ProciseDx

ProciseDx is a point-of-care diagnostic company that focuses on rapid drug concentration monitoring for gastroenterologists treating inflammatory bowel diseases (IBD). Their technology delivers lab-quality results from fingerstick whole blood in under five minutes, enabling immediate treatment decisions during patient visits.

The company offers quantitative immunoassays optimized for monitoring biologic therapies, particularly TNFα inhibitors like infliximab and adalimumab. Their point-of-care platform allows for real-time diagnostic answers, enhancing therapy productivity for IBD patients. ProciseDx was established following a $10.5 million Series A financing round in May 2020 and was acquired by Biosynex S.A. in June 2023 to further advance drug monitoring in the U.S.